Apple's rumored device may help detect heart attacks; China to unveil expedited device review process;

@FierceMedDev: For device companies, clearance for expanded use of key products = more revenue. Story | Follow @FierceMedDev

@MarkHFierce: Singapore's Biosensors International could find itself with a new owner--a Chinese equity firm. Key to a rebound? More | Follow @MarkHFierce

@MichaelGFierce: New gold nanoshells could offer better delivery of cancer drugs using near-infrared light. Release | Follow @MichaelGFierce

@EmilyWFierce: Word on the street is that Apple is developing iWatch technology to detect heart attacks. Article | Follow @EmilyWFierce

> Apple's ($AAPL) rumored health-related device under development would reportedly detect when someone is about to have a heart attack. Story

> Baxter International's ($BAX) board of directors declared a quarterly dividend of 49 cents per Baxter common share. Item

> Covidien ($COV) said it is rolling out a new hydrophilic guidewire for catheter placement and other procedures to treat vascular diseases. Item

> Florida's VeriTeQ gained more CE markings for its new breast implants with enhanced safety technology. Item

> China expects to launch an expedited registration process for cutting-edge medical devices beginning on March 1. Blog

Biotech News

@FierceBiotech: Bayer moves forward in the Factor VIII hemophilia race, but Biogen is still in the lead, analyst says. More | Follow @FierceBiotech

@JohnCFierce: Looks like Actavis wants to buy Forest for $25B - not sure I really get the synergy. Story | Follow @JohnCFierce

@DamianFierce: After snow put the FDA on hold for much of last week, Chelsea Therapeutics expects Northera decision today. Release | Follow @DamianFierce

@EmilyMFierce: Role of adaptor protein could point the way for new diabetes, cancer treatments. More from FierceBiotechResearch. | Follow @EmilyMFierce

> Novartis beefs up its cancer immunotherapy pipeline with a biotech buyout. Story

> Servier stages an entry into high-stakes CAR-T showdown with Novartis. News

> Novimmune banks $66M for immunotherapies as IPO rumors surface. Article

> Akebia swings for a $75M IPO to get its anemia drug into Phase III. Brief

Pharma News

@FiercePharma: Germany may publicize its drug discounts, putting fear into Big Pharma's heart. Story | Follow @FiercePharma

@TracyStaton: Call them the KOLs of biopharma: Our report on the industry's most influential people. Report | Follow @TracyStaton

@EricPFierce: FDA Commish Hamburg hopeful about cooperation from Indian regulators but some were less enthused. News | Follow @EricPFierce

@CarlyHFierce: Best-read special report over Presidents' Day weekend: Top 10 generics makers by 2012 revenue. More | Follow @CarlyHFierce

> Actavis inks $25B deal for Forest in bid to build its brand stable. Piece

> Indian regulator says his agency will not expect domestic drugmakers to hit FDA standards. Item

CRO News

> Quintiles notches its first-ever $1B quarter as sales boom. Earnings

> Parexel's rebranding makes a perceptible shift in its eClinical biz. Story

> Charles River's turnaround pays off with a strong 2013. Story

> Theorem takes a dive into analytics with latest deal. News

> After a 'pivotal' year, AMRI expects another leap in 2014. Article

> Chiltern inks a deal with Karolinska Development. Item

Biotech IT News

> Illumina takes a leaf out of the tech playbook with its genomics startup accelerator. Story

> Twitter explains how Boehringer is winning on social media. Article

> MIT proposes using robotic arms to enable smaller, cheaper stroke trials. Story

> Data science consortium outlines a vision for the future of genomic Big Data. News

> CamNtech gets an FDA nod as wearable devices advance into clinical trials. Article

> China cracks down on 'false' bird flu rumors on social media. Brief

Biotech Research News

> Role of adaptor protein could point the way for new diabetes, cancer treatments. Story

> Stem cell switch in neural cells could help treat neurological disorders. Article

> GlaxoSmithKline joins a $115M antibiotics development initiative. News

> MedImmune, UCSF strike translational research deal. News

> BioLineRx shows effectiveness of leukemia drug in preclinical study. Article

> Compound protects mice from Parkinson's-like motor loss. Item

Pharma Manufacturing News

> Mylan recalls injectable drugs after pieces of label found in some vials. News

> FDA's Hamburg comes back from India with high hopes about quality standards. Article

> Shire gets FDA nod for a second U.S. plant to make Vpriv. Story

> Ben Venue Labs may be closed but it is still recalling products. News

> Hikma's remediation costs have been offset by doxycycline sales. Story

> Amgen responds to FDA warning letter over drug/device combos. Brief

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.